Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: A matched pair analysis-Reference-Cited by-同舟云学术

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: A matched pair analysis

Published:2019-01-04 Issue:9 Volume:144 Page:2347-2354
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Henricks Linda M.¹²^ORCID,van Merendonk Lisanne N.¹²,Meulendijks Didier¹²³,Deenen Maarten J.⁴⁵,Beijnen Jos H.⁶⁷,de Boer Anthonius⁷,Cats Annemieke⁸,Schellens Jan H.M.¹²⁷

Affiliation:

1. Division of Pharmacology; The Netherlands Cancer Institute; Amsterdam the Netherlands

2. Department of Clinical Pharmacology, Division of Medical Oncology; The Netherlands Cancer Institute; Amsterdam the Netherlands

3. Dutch Medicines Evaluation Board (CBG-MEB); Utrecht The Netherlands

4. Department of Clinical Pharmacy, Catharina Hospital; Eindhoven The Netherlands

5. Department of Clinical Pharmacy and Toxicology; Leiden University Medical Center; Leiden the Netherlands

6. Department of Pharmacy & Pharmacology; The Netherlands Cancer Institute; Amsterdam the Netherlands

7. Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences; Faculty of Science, Utrecht University; Utrecht the Netherlands

8. Department of Gastrointestinal Oncology, Division of Medical Oncology; The Netherlands Cancer Institute; Amsterdam the Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.32022/fullpdf

Reference30 articles.

1. Safety of capecitabine: a review;Mikhail;Expert Opin Drug Saf,2010

2. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review);Milano;Anticancer Res,1994

3. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil;Van Kuilenburg;Eur J Cancer,2004

4. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency;Van Kuilenburg;Clin Cancer Res,2001

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DPYD Pharmacogenetics: To Opt-in or to Opt-out;JCO Oncology Practice;2024-08

2. DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review;British Journal of Cancer;2024-06-17

3. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants;JCO Precision Oncology;2024-05

4. Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series;Journal of the National Comprehensive Cancer Network;2024-05

5. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer;Clinical and Translational Science;2024-05